Neue Studie: Long-Covid-Patienten haben offenbar Autoimmunerkrankung
Covid19-Sources
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF
SARS-CoV-2 generates amyloid in cerebral spinal fluid
COVID-19: Lungen-MRT zeigt Langzeitschäden bei Kindern und...
An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines
The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England
COVID raises risk of long-term brain injury, large U.S. study finds
Yunlong Richard Cao on Twitter
SARS-CoV-2 Infection and New-Onset Type 1 Diabetes Among Pediatric Patients
COVID-19 infection may increase risk of type 1 diabetes, suggests nationwide study of 1.2 million children
Post-COVID-19 syndrome: retinal microcirculation as a potential marker for chronic fatigue
Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
Household transmission of the SARS-CoV-2 Omicron variant in Denmark
Jeff Bergheim on Twitter
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk
Effects of Vaccination and Previous Infection on Omicron Infections in Children | NEJM
Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
This situation, i.e., observed ADE without neutralization at a low dilution of serum, is unfavorable for protection against infection. However, it must be remembered that, in contrast to the above-mentioned Ab-involved adverse events, protective cellular immunity is also induced and is involved in anti-SARS-CoV-2 responses in vivo32. Therefore, as a whole, this Ab-mediated adverse potential during virus expansion and the opposing protective effects by T-cell immunity might make it more difficult to recognize the involvement of ADE in SARS-CoV-2 reinfection or resurrection in vivo12. Six volunteers treated with the mRNA vaccine in this study maintained an uninfected state for approximately 8 months after the second vaccination, and also had a third vaccination. Therefore, there is no suggestive information between the data based on in vitro analyses (Fig. 3, Supplemental Figs. 6 and 7) and the clinical observations. To make clear the relationship between clinical variations and ADE observed in in vitro analyses, further investigations using a larger number of samples will be required.
Ziyad Al-Aly, MD on Twitter
Anti-cardiac troponin antibodies in clinical human disease: a systematic review
The majority of severe COVID-19 patients develop anti-cardiac autoantibodies
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein
Do you keep getting colds after COVID? Here's what we know about how COVID changes your immune system
Global severity of excess mortality
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Severe COVID-19 impairs the immune system for longer than 6 months
Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection
Impaired function and delayed regeneration of dendritic cells in COVID-19
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection - BMC Medicine